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Objective: To determine the proportion of patients with Carcinoma of the Prostate in patients presenting 
with Lower Urinary Tract Symptoms. 
Methods: This was a four years prospective case finding study of patients aged 50 years and above with 
Lower Urinary Tract Symptoms (LUTS) in a private hospital in Dar-Es Salaam. Investigations included 
renal function tests, Prostate Specific Antigen (PSA) and prostatic biopsy.  
Results: Of the 201 consecutive patients with LUTS, 86.1% had BPH while 13.9% had Prostate Carcinoma 
(CP) with an average PSA of 51.99 ng/ ml. Digital rectal examination (DRE) was abnormal in 23 cancer 
patients. In 2 patients diagnosis followed finding a raised PSA. In 3 patients carcinoma was an incidental 
finding following TURP. Treatment consisted of orchidectomy in 24 patients, Lutenizing Hormone Releasing 
Hormone (LHRH) agonist (Zoladex) in two while one patient received radiotherapy.  Two of the patients 
who had incidental CP finding with low Gleason score were on watchful waiting. 
Conclusion: Case finding rather than community screening for prostate cancer is preferred due to economic 
reasons. PSA when available is a useful additional investigation. Efforts should be made to detect the disease 




Patients with prostate cancer may present with 
voiding symptoms suggestive of bladder outlet 
obstruction or those related to metastatic disease. The 
prevalence of prostate cancer continues to increase 
with age, and after age 50, both incidence and 
mortality rate from prostate cancer increase at a near 
exponential rate1.  
 
At present, prostate cancer is the most common 
cancer diagnosed in men in the United States and the 
second most common cause of cancer death. Blacks 
living in the USA have a higher incidence rate of 
clinical prostate cancer than white men of similar 
education and socio-economic classes at all ages2. 
Furthermore, black men are routinely diagnosed with 
late stage disease, and survival rates, even when 
correlated for stage, are uniformly lower for black 
men. The histological diagnosis of prostate cancer is 
made, in the majority of cases, by prostatic needle 
biopsy.  Thus, suspicion of prostate cancer is most 
often raised by abnormalities found on digital rectal 
examination (DRE), or serum prostate-specific 
antigen (PSA) elevations. 
 
Routine use of PSA increases the detection of 
prostate cancer over that of DRE, improves the 
predictive value of the DRE for cancer, and increases 
the detection of prostate cancers that are organ 
confined yet significant in terms of size and grade.   
 
 
PSA is the single test with the highest positive 
predictive value for cancer of the prostate 3.   
 
It has been reported in different studies in screened 
populations that the approximate chance of cancer on 
biopsy is 1 in 50 for men with PSA levels below 4.0 
ng/ml3, 1 in 4 for PSA levels of 4.0 to 10 ng/ml, and 
1 in 2 to 3 for PSA levels greater than 10 ng/ml4,5.  
PSA increases the predictive value of the DRE for 
cancer of the prostate6,7.  A decrease in the mortality 
rate of prostate cancer following introduction of 
screening has been reported8,9.    
 
In developing countries however, health provision is 
sub-optimal due to poor economy, and screening 
procedures cannot be done due to cost constraints. It 
follows therefore that the use of PSA as a screening 
tool for CP in the community is not feasible10,11. 
Introduction of new diagnostic tests in developing 
countries are delayed and when available are 
expensive and inaccessible to the general public. 
When introduced few private laboratories own them. 
This prohibits the tests to be used for screening 
purposes.  PSA was introduced in Tanzania five years 
ago. This paper presents the experience on case 
finding of prostate cancer in patients presenting with 
lower urinary tract symptoms (LUTS) in a private 
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Patients and Methods 
This was a prospective case finding study of four 
years in a private hospital in the centre of Dar-Es 
Salaam during the period of January 2000 to 
December 2003. Patients eligible for this study were 
all those who were 50 years or more who presented 
with lower urinary tract symptoms requiring 
investigations and treatment. The hospital had one 
working urologist who saw all patients presenting 
with urology problems. Those patients had a history 
and physical examination done except digital rectal 
examination (DRE), which was carried out after 
blood for PSA had been drawn.  
 
Other investigations done included serum creatinine, 
abdominal ultrasound of the kidney, ureter, bladder 
and prostate. The hospital has no rectal probe for 
Trans-rectal ultrasound (TRUS). The other 
investigations were tailored to the other presenting 
symptoms and signs of the patient. Those who had 
urethral stricture with a normal PSA and DRE were 
however excluded, as the tissue biopsy was not 
obtained. The age of the patient and the presenting 
symptoms were recorded. The urologist documented 
all the findings of the DRE. Those patients who had 
abnormal DRE findings in the prostate had a tru-cut 




Patients who had an elevated PSA without suspicious 
nodule had sextant core biopsies done. Cut off point 
for PSA in the lab was 4ng/ml.  
 
Patients who had significant urinary symptoms were 
treated by TURP or open prostatectomy. Tissues 
from prostatectomy were examined to determine 
whether prostate cancer was evident. The Gleason 
score was also done and recorded at histology.  
 
Patients with prostate cancer were treated by 
Orchidectomy, Lutenizing Hormone Releasing 
Hormone (LHRH) agonist (Zoladex), Radiotherapy 
or watchful waiting according to the stage and grade 




A total of 219 consecutive patients with lower 
urinary tract symptoms were seen at the hospital. 
However 201 are presented in this study. Eighteen 
patients who had LUTS secondary to urethral 
stricture were excluded as none of them had prostate 
biopsy done. The age range of the patients was from 
50 to 98 with a mean of 68.4 years. The majority 
(72.1%) of the patients belonged to the age groups 
60–69 and 70–79 (Table 1).  
 
Table 1. Age distribution of the studied patients 
 
Age Group Number Of Patients 
 
Percentage 
50-59 35 17.4 
60-69 69 34.3 
70-79 76 37.8 
80-89 17 8.5 
>90 4 2 
Total 201 100 
 
Table 2. Presenting features of the patients 
 
Presentation Number Of Patients Percentage 
Bothersome symptoms (LUTS) 101 50.2 
Retention of urine 86 42.8 
Urinary bladder stones 3 1.5 
Inguinal Hernia 2 1 
Heamaturia 7 3.5 
Paraplegia 2 1 
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Table 3. Detection of Carcinoma of the prostate. 
 
Method Of Detection Number Of Patient 
Abnormal DRE 23 
Raised PSA 2 
Incidental Carcinoma 3 
 
 
The reason for consultation was significant 
bothersome symptoms of lower urinary tract in 101 
(50.2%) of the patients and retention of urine in 86 
(42.8%). The other presenting features were stones, 
hernia and UTI.         Two patients had paraplegia 
due to metastasis of CP to the spine (Table 2). Taking 
all patients together the average PSA measured by 
Min-Vadas France BioMurex Lab reagents was 
13.12ng/ml. However the average PSA in the 173 
patients with BPH was 6.71ng/ml. Patients with 
prostatic cancer had an average PSA of 51.99ng ml.
 
The range of PSA was 0.68 to >100 ng/ml. The upper 
range in this laboratory was indicated as more than 
100 a draw back to the average results of PSA to 
cancer group of patients. 
 
Twenty-eight (13.9%) of all patients had prostate 
cancer and had an average age of 68.7 years. Apart 
from lower urinary tract symptoms some patients 
presented with metastatic symptoms of paraplegia, 
low back pain, anaemia, oedema of the legs, weight 
loss and general weakness. The DRE was abnormal 
in 23 patients together with raised PSA. Two patients 
without abnormality of DRE were diagnosed CP on 
finding a raised PSA. The other three patients were 
diagnosed as incidental findings from TURP with a 
normal PSA (Table 3). Twenty-four patients had  
 
Orchidectomy as the treatment (one patient started 
with Zoladex and had to have Orchidectomy done 
due to cost constraint); one patient was treated with 
LHRH agonist Zoladex while one patient received 
radiotherapy outside the country. Two of the three 
patients who had incidental carcinoma with a 
favourable Gleason score were managed on watchful 
waiting with regular PSA checks.  
Discussion 
 
The advantage of early diagnosis of prostate cancer 
and its treatment by radical surgery and its influence 
to survival is well documented12. Being 
asymptomatic in the early stage, prostate cancer 
discovery is facilitated by the use of screening and 
PSA, which has increased the detection and lead to 
the recommendation of mass screening for it13,14. 
However the debate on the logic of treatment of 
localized disease, which is usually found during 
screening with the slow growth of the tumour has 
also been posed15.  Moreover community screening 
of prostate cancer by use of PSA is expensive and 
though desirable is prohibitive in poor countries 
where case finding studies will remain the main 
source of data. 
 
The mean age in this series of patients was slightly 
higher than those reported in one publication in this 
continent10. All of the patients had significant lower 
urinary tract symptoms. The majority of the patients 
(86.1%) were found to have BPH while 13.9% had 
prostate cancer. This ratio is slightly higher than that 
reported in Egypt10 but is comparable with findings in 
another study which on top of DRE and PSA used 
Transrectal Ultrasound (TRUS) which could 
probably explain the higher pick up ratio16. The high 
ratio in our series of patients, may be an indication of 
a possibly high incidence of Carcinoma of the 
Prostate in our population in black Africa.  
     
Indeed prostate cancer rarely causes symptoms early 
in the course of disease because the majority (70-
85%) of adenocarcinoma arises in the periphery of 
the gland (peripheral zone), distant from the urethra.  
In the other group of patients (15-30%), the cancer 
develops from the other zones.  The presence of 
symptoms as a result of prostate cancer suggests 
coexistence with BPH, a locally advanced or 
metastatic disease, as was the case in the majority of 
our patients who had advanced disease at diagnosis. 
Only five patients out of the twenty-eight patients 
were diagnosed with early malignancy and would 
qualify for Radical Prostatectomy. 
 
All suspicious lesions at DRE underwent a biopsy 
and confirmed the disease a high pick up rate.  In one 
series it was reported that approximately 50% of 
suspicious lesions represented cancer on prostate 
biopsy 17.  Because of the significant risk of prostate 
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who have DRE abnormalities, regardless of the PSA 
level, since there is still a chance, however small of 
CP even when PSA level is less than 4 ng/ml 3.  It is 
of paramount important to note here that till now 
clinical presentation and   abnormal DRE remains the 
main way of diagnosis of CP in most of the hospitals 
in this country. However, we also emphasize that 
DRE misses from 23% to 45% of the cancers that are 
subsequently found with prostatic biopsies done for 
serum PSA elevation or Trans-rectal ultrasound 
abnormalities18,19. In our series five patients would 
have been missed since their DRE was normal. 
 
The studied population here is not a representative 
sample as this was a selected group who can afford 
treatment in a private hospital. Secondly the number 
of patients is small to draw a conclusion but the 
proportion of CP is high. Also the stage at which the 
disease at diagnosis was advanced similar to What 
others report that prostate cancer detected by DRE in 
screened and unscreened populations of men are 
pathologically advanced in more than 50% of men15. 
Where possible in developing countries a 
combination of DRE and PSA in patients with LUTS 
should be used to pick up more cases with CP. There 
is however a need to establish the true prevalence of 
CP in a black African country by a well planned 
randomized study using PSA, DRE and TRUS. 
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